Riboflavin, in the form of flavin adenine dinucleotide (FAD), is shown as the required cofactor for this reaction, which consumes NADPH and a proton (H + ) and releases NADP +
However, since it can be assumed that noticeably more people will benefit, our data provide a good basis for further research and considerations, as they most likely represent a minimum of the estimated eligibility for GLP-1 RA therapy
Statements Data availability statement The datasets presented in this article are not readily available because of ethical and privacy restrictions
Estimates suggest one in eight adults use GLP-1 medications
Final Thoughts Sublingual semaglutide is more than just an alternative to injections it represents a significant opportunity to improve access, adherence and possibly unlock new therapeutic applications
Efficacy of tirzepatide versus semaglutide in achieving therapeutic targets in type 2 diabetes: a post hoc analysis of SURPASS-2